THIO sequenced with Libtayo extended overall survival in those with non–small cell lung cancer who progressed on two or more ...

BCC is new territory for cancer immunotherapies however, and Libtayo is the first drug in the PD-1/PD-L1 inhibitor class to get go-ahead in this common form of skin cancer. It's been cleared for ...

A novel AI model was able to achieve 99.86% accuracy for diagnosing skin conditions, even in people with darker skin tones or ...

This positive news in skin cancer is notable for several reasons: LIBTAYO gained FDA approval in 2018 for CSCC and has also been approved to treat non-small cell lung cancer (NSCLC) as well.

Regeneron's Q4 earnings report shows revenue growth, stable EYLEA sales, dividend announcement, and impressive growth for ...

Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment for ...

Moments after Regeneron CEO Len Schleifer scolded analysts for asking too many questions about the disappointing sales of eye ...

CSCC is the second most common type of skin cancer, with approximately 1.8 million cases diagnosed in the US every year. Libtayo is designed to block cancer cells from using the PD-1 pathway to ...

Becky Kamowitz was appointed executive director of The Skin Cancer Foundation in January 2025. She talks about the ...

Regeneron Pharmaceuticals beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema ...

Immuneering plans to evaluate IMM-1-104 in combination with Libtayo in patients with advanced non-small cell lung cancer in its ongoing Phase ...

Adjuvant treatment with cemiplimab (Libtayo) significantly improves disease ... department of medical oncology at the Peter MacCallum Cancer Centre in Melbourne, Australia.